[{"orgOrder":0,"company":"Intract Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Infliximab","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Intract Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intract Pharma \/ SGS Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Intract Pharma \/ SGS Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by Intract Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 18, 2022

                          Lead Product(s) : Infliximab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : SGS Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank